| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2803104201179 | 310420117 | SIMVASTATIN/MYLAN F.C.TAB 10MG/TAB BT x 30 (σε blisters AL/PVC/PVDC) (σε blisters AL/PVC/PVDC) | 1.26 | 1.32 | 1.82 |
| 05/2018 | 2803104202176 | 310420217 | SIMVASTATIN/MYLAN F.C.TAB 20MG/TAB BTx30(BLISTERS AL/PVC/PVdC) AL/PVC/PVdC) | 5.17 | 5.42 | 7.47 |
| 05/2018 | 2803104203173 | 310420317 | SIMVASTATIN/MYLAN F.C.TAB 40MG/TAB BTx30 (BLISTERS ΑL/PVC/PVdC) ΑL/PVC/PVdC) | 6.99 | 7.33 | 10.10 |
For the treatment of hypercholesterolemia.
The 6-membered lactone ring of simvastatin is hydrolyzed <i>in vivo</i> to generate the beta,delta-dihydroxy acid, an active metabolite structurally similar to HMG-CoA (hydroxymethylglutaryl CoA). Once hydrolyzed, simvastatin competes with HMG-CoA for HMG-CoA reductase, a hepatic microsomal enzyme. Interference with the activity of this enzyme reduces the quantity of mevalonic acid, a precursor of cholesterol.
Absorption of simvastatin, estimated relative to an intravenous reference dose, in each of two animal species tested, averaged about 85% of an oral dose. In animal studies, after oral dosing, simvastatin achieved substantially higher concentrations in the liver than in non-target tissues.
3 hours
Following an oral dose of 14C-labeled simvastatin in man, 13% of the dose was excreted in urine and 60% in feces.